natgillin/translations-raw huggingface dataset:
• Hver 1 mg tablet indeholder guanfacinhydrochlorid svarende til 1 mg guanfacin
• Each 1 mg tablet contains guanfacine hydrochloride equivalent to 1 mg of guanfacine
• 4 mg depottabletter er ovale og grønne, hårde tabletter, præget med 4MG på den ene side og med 503 på den anden side.
• The 4 mg prolonged-release tablets are oval and green, hard tablets, debossed with 4MG on one side and 503 on the other side.
EU/1/15/1040/001 7 depottabletter EU/1/15/1040/002 28 depottabletter
EU/1/15/1040/001 7 prolonged-release tablets EU/1/15/1040/002 28 prolonged-release tablets
Intuniv 1 mg tablet Hver tablet indeholder guanfacinhydrochlorid svarende til 1 mg guanfacin.
Intuniv 1 mg tablet Each tablet contains guanfacine hydrochloride equivalent to 1 mg of guanfacine.
• Hver 4 mg tablet indeholder guanfacinhydrochlorid svarende til 4 mg guanfacin
• Each 4 mg tablet contains guanfacine hydrochloride equivalent to 4 mg of guanfacine
EU/1/15/1040/008 28 depottabletter EU/1/15/1040/009 84 depottabletter
EU/1/15/1040/008 28 prolonged-release tablets EU/1/15/1040/009 84 prolonged-release tablets
• Hver 2 mg tablet indeholder guanfacinhydrochlorid svarende til 2 mg guanfacin
• Each 2 mg tablet contains guanfacine hydrochloride equivalent to 2 mg of guanfacine
Intuniv 4 mg tablet Hver tablet indeholder guanfacinhydrochlorid svarende til 4 mg guanfacin.
Intuniv 4 mg tablet Each tablet contains guanfacine hydrochloride equivalent to 4 mg of guanfacine.
Intuniv 2 mg tablet Hver tablet indeholder guanfacinhydrochlorid svarende til 2 mg guanfacin.
Intuniv 2 mg tablet Each tablet contains guanfacine hydrochloride equivalent to 2 mg of guanfacine.
Hver tablet indeholder guanfacinhydrochlorid svarende til 1 mg guanfacin.
Each tablet contains guanfacine hydrochloride equivalent to 1 mg of guanfacine.
• Hver 3 mg tablet indeholder guanfacinhydrochlorid svarende til 3 mg guanfacin
• Each 3 mg tablet contains guanfacine hydrochloride equivalent to 3 mg of guanfacine
Intuniv 2 mg depottabletter Guanfacin
Intuniv 2 mg prolonged-release tablets Guanfacine
Intuniv 3 mg tablet Hver tablet indeholder guanfacinhydrochlorid svarende til 3 mg guanfacin.
Intuniv 3 mg tablet Each tablet contains guanfacine hydrochloride equivalent to 3 mg of guanfacine.
Kontakt lægen eller apotekspersonalet, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke kan tåle eller fordøje visse sukkerarter.
If you have been told by your doctor that you cannot tolerate or digest some sugars, talk to your doctor or pharmacist before taking this medicine.
EU/1/15/1040/006 28 depottabletter EU/1/15/1040/007 84 depottabletter
EU/1/15/1040/006 28 prolonged-release tablets EU/1/15/1040/007 84 prolonged-release tablets
Hver tablet indeholder guanfacinhydrochlorid svarende til 4 mg guanfacin.
Each tablet contains guanfacine hydrochloride equivalent to 4 mg of guanfacine.
Intuniv 1 mg depottabletter Guanfacin
Intuniv 1 mg prolonged-release tablets Guanfacine
Intuniv 4 mg depottabletter Guanfacin
Intuniv 4 mg prolonged-release tablets Guanfacine
Nedsat puls
Heart rate decreased
• svaghedsfølelse (asteni)
• feeling weak (asthenia)
Intuniv 3 mg depottabletter Guanfacin
Intuniv 3 mg prolonged-release tablets Guanfacine
Almene symptomer Træthed
General disorders Fatigue
Hver tablet indeholder guanfacinhydrochlorid svarende til 2 mg guanfacin.
Each tablet contains guanfacine hydrochloride equivalent to 2 mg of guanfacine.
Hver tablet indeholder guanfacinhydrochlorid svarende til 3 mg guanfacin.
Each tablet contains guanfacine hydrochloride equivalent to 3 mg of guanfacine.
Intuniv 3 mg depottabletter
Intuniv 3 mg prolonged-release tablets
Hvis du har taget for meget Intuniv
If you take more Intuniv than you should
• social behandling
• social therapy
Intuniv 4 mg depottabletter
Intuniv 4 mg prolonged-release tablets
Intuniv 2 mg depottabletter
Intuniv 2 mg prolonged-release tablets
Respondenter
Excipients
Affektlabilitet
Affect lability
Intuniv 1 mg depottabletter
Intuniv 1 mg prolonged-release tablets
Perikon
Pallor
• Produktresumé og indlægsseddel
• Summary of Product Characteristics (SmPC) and Package Leaflet
Hvad er colistin?
What is colistin?
14. juli 2016
14 July 2016
Disse anvisninger gennemgik kritiske oplysninger om
This advice critically reviewed information on
Europa-Kommissionen traf en afgørelse den 14. juli 2016.
The European Commission issued a decision on 14 July 2016.
Colistin anvendes til behandling og forebyggelse af sygdomme, der skyldes følsomme bakterier (f.eks. Escherichia coli) hos svin, fjerkræ, kaniner, kvæg, får og geder.
Colistin is used for the treatment and prevention of diseases caused by sensitive bacteria (e.g. Escherichia coli) in pigs, poultry, rabbits, cattle, sheep and goats.
Resultatet af en indbringelsesprocedure i henhold til artikel 35 i direktiv 2001/82/EF (EMEA/V/A/111)
Outcome of a referral procedure under Article 35 of Directive 2001/82/EC (EMEA/V/A/111)
2 om at begrænse indikationerne, måldyrearterne og behandlingsvarigheden for de pågældende produkter og tilføje advarsler om forsvarlig brug i produktinformationen.
2 restricting the indications, target species, and duration of treatment of the concerned products, as well as adding prudent use warnings to the product information.
anvendelsen af colistin hos fødevareproducerende dyr i EU, dets effekt på udviklingen af resistens over for denne kategori af antimikrobielle stoffer hos bakteriearter, der er vigtige for menneskers og dyrs sundhed, og den mulige indvirkning heraf på menneskers og dyrs sundhed.
the use of colistin in food-producing animals in the EU, its effect on the development of resistance to this category of antimicrobial agents in bacterial species that are of importance for human and animal health and the possible impact on human and animal health.
Colistin tilhører den gruppe antibiotika, der kaldes polymyxiner.
Colistin belongs to the polymyxin group of antibiotics.
CVMP blev anmodet om at gennemgå markedsføringstilladelserne og de tilgængelige data for at sikre ansvarlig anvendelse af stoffet med henblik på at beskytte dyrs sundhed og begrænse muligheden for en fremtidig risiko for folkesundheden.
The CVMP was requested to review the marketing authorisations and the available data in order to ensure responsible use of the substance in protecting animal health and limiting the possibility of future risk to public health.
Der er tale om veterinærlægemidler, der indeholder colistin kombineret med 14 forskellige antimikrobielle stoffer fra forskellige klasser, f.eks. β-laktamer, tetracykliner, makrolider, sulfonamider og trimethoprim (se bilag I under fanebladet "All documents").
These include veterinary medicinal products containing combinations of colistin with 14 different antimicrobial substances, belonging to different classes e.g. β-lactams, tetracyclines, macrolides, sulfonamides and trimethoprim (see Annex I on the 'All documents' tab).
Colistin kombineret med andre antimikrobielle stoffer fås til gruppebehandling af gastrointestinale og respiratoriske infektioner hos fødevareproducerende dyr i forskellige EU-medlemsstater.
Combinations of colistin with other antimicrobials are available for group treatments of gastro-intestinal and respiratory infections in food-producing animals in different European Member States.
Spørgsmål og svar vedrørende veterinærlægemidler, der indeholder colistin i kombination med andre antimikrobielle stoffer til oral administration EMA/461505/2016
Questions and answers on veterinary medicinal products containing colistin in combination with other antimicrobial substances to be administered orally EMA/461505/2016
EMA's Udvalg for Lægemidler til Dyr (CVMP) har konkluderet, at det generelle benefit/risk-forhold for de nævnte veterinærlægemidler er negativt, dels som følge af den manglende kliniske relevans, dels på baggrund af, at overeksponering for colistin kan udgøre en potentiel risiko for dyrs og menneskers sundhed ved at fremskynde forekomsten af resistens mod colistin.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the overall benefit-risk balance for the aforementioned products is negative, due to a lack of clinical relevance and in view of over-exposure of colistin that could pose a potential risk to animal and human health from an acceleration of the occurrence of colistin resistance.
Desuden blev markedsføringstilladelsesindehaverne anmodet om at godtgøre fordelene ved at bruge kombinationsprodukter, der indeholder colistin, i forhold til monoterapi til behandling af de respektive sygdomme, navnlig under hensyntagen til CVMP's retningslinjer for kombinationspræparater
In addition, the marketing authorisation holders were asked to justify the benefits of using a colistin combination product over the use of monotherapy for the treatment of the respective conditions, particularly taking into account the CVMP guideline on pharmaceutical fixed combination products
Efter vurdering af de foreliggende data konkluderede CVMP, at der ikke kan påvises nogen fordele ved anvendelse af colistin kombineret med andre stoffer i forhold til monoterapi, og at der ikke kan fastsættes nogen egnede risikominimeringsforanstaltninger til imødegåelse af den identificerede potentielle risiko for menneskers sundhed, da selv begrænset anvendelse af colistin kombineret med andre stoffer anses for unødvendig.
Based on the evaluation of the currently available data, the CVMP concluded that no benefit could be demonstrated when using colistin combination products instead of monotherapy and no feasible risk mitigation measures could be identified to address the identified potential risk for human health, as even limited use of colistin combination products was considered unnecessary.
Spørgsmål og svar vedrørende veterinærlægemidler, der indeholder colistin i kombination med andre antimikrobielle stoffer til oral administration
Questions and answers on veterinary medicinal products containing colistin in combination with other antimicrobial substances to be administered orally
Kommissionenes beslutning om markedsføringstilladelse i henhold til artikel 35 i Europa Parlamentets og Rådets direktiv 2001/82/EF for alle veterinærlægemidler, som indeholder "Colistin" til oral administration ((2015)1916 of 16/03/2015) http://ec.europa.eu/health/documents/community-register/html/vo25478.htm
Commission Decision concerning, in the framework of Article 35 of Directive 2001/82/EC of the European Parliament and of the Council, the marketing authorisations for all veterinary medicinal products containing "Colistin" to be administered orally ((2015)1916 of 16/03/2015) http://ec.europa.eu/health/documents/community-register/html/vo25478.htm
Den 21. april 2016 afsluttede Det Europæiske Lægemiddelagentur (EMA) en undersøgelse af virkning og antimikrobiel resistens, hvad angår alle veterinærlægemidler, der indeholder colistin i kombination med andre antimikrobielle stoffer til oral administration.
On 21 April 2016, the European Medicines Agency (the Agency) completed a review of the effectiveness of and antimicrobial resistance to all veterinary medicinal products containing colistin in combination with other antimicrobial substances to be administered orally.
Hvorfor blev veterinærlægemidler, der indeholder colistin i kombination med andre antimikrobielle stoffer til oral administration, undersøgt?
Why were veterinary medicinal products containing colistin in combination with other antimicrobial substances reviewed?
CVMP anbefalede, at alle markedsføringstilladelser for veterinærlægemidler, der indeholder colistin i kombination med andre antimikrobielle stoffer til oral administration, inddrages i hele Den Europæiske Union (EU).
The CVMP recommended that all marketing authorisations for veterinary medicinal products containing colistin in combination with other antimicrobial substances to be administered orally should be withdrawn throughout the European Union (EU).
CVMP anbefalede derfor, at alle markedsføringstilladelser for alle veterinærlægemidler, der indeholder colistin i kombination med andre antimikrobielle stoffer til oral administration, inddrages.
Therefore the CVMP recommended that all marketing authorisations for all veterinary medicinal products containing colistin in combination with other antimicrobial substances to be administered orally should be withdrawn.
I maj 2015 indledte Europa-Kommissionen en indbringelsesprocedure i medfør af artikel 35 i direktiv 2001/82/EF for alle veterinærlægemidler, der indeholder colistin i kombination med andre antimikrobielle stoffer til oral administration.
On 4 May 2015, the European Commission initiated a referral procedure under Article 35 of Directive 2001/82/EC for all veterinary medicinal products containing colistin in combination with other antimicrobial substances to be administered orally.
London, den 13. april 2007 EMEA/CHMP/75285/2007
London, 13 April 2007 EMEA/CHMP/75285/2007
Den endelige udtalelse blev konverteret til en afgørelse truffet af Europa-Kommissionen den 13. april 2007.
The final opinion was converted into a Decision by the European Commission on 13 April 2007.
Voldgiftsproceduren indledtes den 27. juli 2006 med vedtagelsen af liste med spørgsmål.
The arbitration procedure started on 27 July 2006 with the adoption of a list of questions.
Der er påvist et fald i forekomsten af vertebrale frakturer, men ikke i forekomsten af ikke-vertebrale frakturer”.
A reduction in the incidence of vertebral, but not of non-vertebral fractures has been demonstrated”.
Sverige fremsendte begrundelserne for uenigheden til EMEA den 10. juli 2006.
Sweden referred the reasons for disagreement to the EMEA on 10 July 2006.
Indehaveren af markedsføringstilladelsen fremsendte skriftlige redegørelser den 19. oktober 2006.
The Marketing Authorisation Holder provided written explanations on 19 October 2006.
Der blev konstateret betydelige forskelle med hensyn til indikationen til behandling af osteoporose hos mænd, og dette blev anset for at udgøre et alvorligt problem for folkesundheden.
Significant difference has been identified with regard to the indication for treatment of osteoporosis in men and this was considered to be of serious public health concern.
Rapportøren var Dr. Tomas Salmonson, og medrapportøren var Dr. Frits Lekkerkerker.
The Rapporteur was Dr. Tomas Salmonson and Co-Rapporteur(s) was Dr. Frits Lekkerkerker.
Ansøgningen blev ved gentagen anvendelse af den gensidige anerkendelsesprocedure, som blev indledt den 11. oktober 2005, indgivet til følgende berørte medlemsstater (CMS): Belgien, Grækenland og Danmark.
In the repeat use of the Mutual Recognition procedure, which started on 11 October 2005, the application was submitted to the Concerned Member States (CMS): Belgium, Greece and Denmark.
CHMP var af den opfattelse, at benefit/risk-forholdet var gunstigt for følgende indikation: “Behandling af osteoporose hos mænd med forhøjet risiko for brud.
The CHMP considered that the benefit/risk ratio was considered to be favourable in the following indication: “Treatment of osteoporosis in men at increased risk of fracture.
Referencemedlemsstaten var Sverige, og i den første fase af den gensidige anerkendelsesprocedure var de berørte medlemsstater, som allerede havde udstedt markedsføringstilladelse, Tyskland og Polen.
The Reference Member State was Sweden and in the first wave of the mutual recognition procedure, the concerned Member States which have already granted the marketing authorisation were Germany and Poland.
På sit møde i januar 2007 var CHMP på grundlag af de samlede forelagte oplysninger og den faglige drøftelse i udvalget af den opfattelse, at de indsigelser, der havde givet anledning til artikel 29-indbringelsen, ikke bør være til hinder for udstedelse af en markedsføringstilladelse for Alendronat HEXAL og tilknyttede navne.
During their January 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the objections that triggered the Article 29 Referral, should not prevent the granting of a Marketing Authorisation for Alendronate HEXAL and associated names.
Hexal A/S indgav ansøgninger om gensidig anerkendelse af Alendronat HEXAL og tilhørende navne, 10 mg tabletter, på baggrund af den markedsføringstilladelse, Sverige havde udstedt den 3. december 2004.
Hexal A/S submitted applications for mutual recognition of Alendronate HEXAL and associated names, 10 mg tablets on the basis of the marketing authorisation granted by Sweden on 3 December 2004.
Den 24. januar 2007 vedtog CHMP en positiv udtalelse, som anbefalede udstedelse af markedsføringstilladelsen og ændring af referencemedlemsstatens produktresumé, etikettering og indlægsseddel.
Therefore the CHMP issued a positive opinion on 24 January 2007 recommending the granting of the Marketing Authorisation and the amendments of the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State.
UDVALGET FOR HUMANMEDICINSKE LÆGEMIDLER (CHMP) UDTALELSE SOM FØLGE AF EN SAG INDBRAGT I HENHOLD TIL ARTIKEL 29, STK. 41, OM Alendronat HEXAL og tilknyttede navne Internationalt fællesnavn (INN): alendronsyre (i form af alendronatnatriumtrihydrat)
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR Alendronate HEXAL and associated names International Non-Proprietary Name (INN): alendronic acid (as sodium alendronate trihydrate)
Alendronat HEXAL og tilhørende navne, 10 mg tabletter, indeholder alendronsyre i form af alendronatnatriumtrihydrat, som er et biphosphonat, der er indiceret til behandling af postmenopausale patienter med osteoporose.
Alendronate HEXAL and associated names, 10 mg tablets, contains alendronic acid as sodium alendronate trihydrate, which is a bisphosphonate indicated in the treatment of post-menopausal osteoporosis.
De kliniske symptomer er blevet rapporteret meget sjældent fra marken.
This clinical sign has been reported very rarely from the field.
Administrer en dosis på 2 ml i henhold til følgende vaccinationsprogram: Første injektion: fra 3 måneders-alderen.
Administer one dose of 2 ml according to the following vaccination scheme: 1st injection: from 3 months of age.
På dag 2 efter vaccinationen var rektaltemperaturen igen normal.
On day 2 after vaccination, rectal temperatures had returned to normal values.
I et laboratorium studie, der blev ikke observeret nogen bivirkninger efter den første injektion af en enkeltdosis vaccine til kalve.
In one laboratory safety study, no adverse reactions were observed after the first injection of a single dose of vaccine to calves.
Anvend derfor kun vaccinen til denne kategori af dyr i henhold til en benefit/risk-vurdering foretaget af den ansvarlige dyrlæge og/eller de nationale myndigheder, der er ansvarlige for den foreliggende vaccinationspolitik for Bluetongue virus (BTV).
In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/or national Competent Authorities on the current vaccination policies against BTV.
Der foreligger ingen oplysninger om brugen af vaccinen til seropositive dyr, herunder dyr med maternelle antistoffer, men det er vist, at vaccinen er sikker og effektiv hos seropositivt kvæg.
No information is available on the use of the vaccine in animals with maternally derived antibodies however the vaccine has been shown safe and efficacious in seropositive cattle.
− Meget almindelig (mere end 1 ud af 10 dyr, der viser bivirkninger i løbet af en behandling)
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
Lokale reaktioner på mere end 2 cm er almindelige efter en dobbelt overdosis, mens reaktioner på op til 5 cm lejlighedsvis forekommer efter administration af en overdosi; disse forsvinder efter højst 57 dage.
Local reactions of more than 2 cm are common after 2 fold overdose while reactions of up to 5 cm may occasionally occur after overdose administration, these resolve within a maximum of 57 days.
Et revaccinationsprogram skal aftales med den ansvarlige myndighed eller den ansvarlige dyrlæge, der bør tage den lokale epidemiologiske situation med i betragtning.
Any revaccination scheme should be agreed by the Competent Authority or by the responsible veterinarian, taking into account the local epidemiological situation.
Til stimulation af aktiv immunitet mod bluetonguevirus, serotype 8 hos kvæg.
To stimulate active immunity against bluetongue virus, serotype 8 in cattle.
ANVENDELSESMÅDE OG INDGIVELSESVEJ(E) Intramuskulær anvendelse.
METHOD AND ROUTE(S) OF ADMINISTRATION For intramuscular use.
OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE Kartonæske med 1 x 20 ml / Kartonæske med 1 x 100 ml
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Carton box 1 x 20ml / Carton box 1 x 100 ml
10. UDLØBSDATO EXP {måneder/år} Efter anbrud: anvendes straks.
EXPIRY DATE EXP {month/year} Once broached use immediately.
B. BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE UDLEVERING OG BRUG Må kun udleveres efter veterinærrecept.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE Veterinary medicinal product subject to prescription.
Særlige forsigtighedsregler vedrørende brug til dyr: Må kun anvendes til raske dyr.
Special precautions for use in animals: Only use in healthy animals
VETERINÆRLÆGEMIDLETS NAVN ZULVAC 8 Bovis injektionsvæske, suspension, til kvæg
NAME OF THE VETERINARY MEDICINAL PRODUCT ZULVAC 8 Bovis suspension for injection for cattle
6.5 Den indre emballages art og indhold Type I glasflaske (10 doser) eller type II glasflaske (50 doser) med butylelastomer prop. Pakningsstørrelser
Type I glass bottle (10 doses) or type II glass bottle (50 doses) with butyl elastomer closure
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER En dosis på 2 ml vaccine indeholder:
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) One dose of 2 ml of vaccine contains:
Hjælpestofferne (inklusive adjuvanser) som er anført i punkt 6.1 af SPC'et er enten tilladte hjælpestoffer, hvor tabel 1 i bilaget til Kommissionens forordning (EU) Nr. 37/2010 indikerer at
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
4.2 Terapeutiske indikationer med angivelse af dyrearter, som lægemidlet er beregnet til Aktiv immunisering af kvæg fra 3 måneders-alderen til forebyggelse* af viræmi, som er forårsaget af bluetonguevirus, serotype 8.
4.2 Indications for use, specifying the target species Active immunisation of cattle from 3 months of age for the prevention* of viraemia caused by bluetongue virus, serotype 8.
Aktiv immunisering af kvæg fra 3 måneders-alderen til forebyggelse* af viræmi, som er forårsaget af bluetonguevirus, serotype 8.
Active immunisation of cattle from 3 months of age for the prevention* of viraemia caused by bluetongue virus, serotype 8.
kan en medlemsstat i overensstemmelse med medlemsstatens nationale lovgivning forbyde fremstilling, indførsel, besiddelse, salg, levering og/eller anvendelse af veterinærlægemidlet på hele eller en del af sit område, hvis det godtgøres:
a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:
DYREARTER Kvæg.
TARGET SPECIES Cattle
MÆNGDEN AF AKTIVT STOF (AKTIVE STOFFER) En dosis med 2 ml: Inaktiveret bluetonguevirus, serotype 8, stamme BTV-8/BEL2006/02
QUANTITY OF THE ACTIVE SUBSTANCE(S) One dose of 2 ml: Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02
MINDSTEKRAV TIL OPLYSNINGER PÅ SMÅ INDRE PAKNINGER Etiket til hætteglas 20 ml
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial label 20 ml
INDLÆGSSEDDEL TIL: ZULVAC 8 Bovis injektionsvæske, suspension, til kvæg
PACKAGE LEAFLET FOR: ZULVAC 8 Bovis suspension for injection for cattle
1348 Louvain-la-Neuve BELGIEN
Rue Laid Burniat 1 1348 Louvain-la-Neuve